- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 207/24 - Oxygen or sulfur atoms
Patent holdings for IPC class C07D 207/24
Total number of patents in this class: 99
10-year publication summary
|
2
|
6
|
12
|
5
|
3
|
8
|
6
|
6
|
6
|
2
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Omeros Corporation | 304 |
5 |
| Novartis AG | 10346 |
4 |
| Vettore, LLC | 17 |
4 |
| Pfizer Inc. | 3366 |
3 |
| Merck Patent GmbH | 5668 |
3 |
| BioCryst Pharmaceuticals, Inc. | 179 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2968 |
3 |
| Bristol-myers Squibb Company | 4812 |
2 |
| 3m Innovative Properties Company | 17512 |
2 |
| Janssen Pharmaceutica N.V. | 3233 |
2 |
| Allergan, Inc. | 2214 |
2 |
| Northwestern University | 3501 |
2 |
| Eli Lilly and Company | 4033 |
2 |
| MedImmune Limited | 612 |
2 |
| National Institute of Biological Sciences, Beijing | 100 |
2 |
| NDSU Research Foundation | 242 |
2 |
| Shanghai Puyi Chemical Technology Co. Ltd | 2 |
2 |
| Vironova Thionation AB | 5 |
2 |
| Petra Pharma Corporation | 36 |
2 |
| Suzhou Abogen Biosciences Co., Ltd. | 75 |
2 |
| Other owners | 48 |